About twenty year’s innovative research and development in science and drug discovery. A pioneer and leader in revolutionary cardiomyocyte therapies worldwide.

CARDIOMYOCYTE THERAPY | MECHANISM

Core
Technology

Cardiomyocyte Therapy

CORE TECHNOLOGY

World-leading science and cutting-edge technology, focus on the fundamental principle of diseases, target and mechanism-of-action based drug research and development

  • Leading technology

  • pathogenesis

  • mechanism of target

Pipeline

  • Neucardin®(HFrEF)

    Recombinant human neuregulin-1 (Neucardin®), developed by Zensun, is a novel genetically engineered biologic ...

    MORE
  • Neucardin®(HFpEF)

    Heart failure with a preserved ejection fraction(HFpEF)is characterized by incomplete relaxation and reduced compliance of cardiomyocytes.

    MORE
  • Neucardin®(AMI)

    Heart failure with a preserved ejection fraction(HFpEF)is characterized by incomplete relaxation and reduced compliance of cardiomyocytes.

    MORE

地址:上海市浦东张江高科技园区居里路68号沪ICP备06030993号